ÉϺ£Í¬Ö¾ - ÉϺ£Í¬Ö¾ÁÄÌìÊÒ - ÉϺ£Í¬Ö¾½»ÓÑ - Mollis Shanghai UniClub

ÉϺ£Í¬Ö¾ - ÉϺ£Í¬Ö¾ÁÄÌìÊÒ - ÉϺ£Í¬Ö¾½»ÓÑ

 ÕÒ»ØÃÜÂë
 »¶Ó­¼ÓÈë һͬ×ÊѶ
http://www.danlan.org/new/UploadFile/201712/20171214/ea_20
http://www.danlan.org/new/UploadFile/201712/20171201/ea_20171211
http://www.danlan.org/new/UploadFile/20170
http://www.danlan.org/new/UploadFile/201712/20171212/ea_20171212221732992.jpg ɽÎ÷Ê¡ÎÀÉú¼

Ĭɳ¶«¿¹°¬ÐÂÒ©ÔÚÃÀ½øÈëÉó²é

2018-7-31 09:34| ·¢²¼Õß: admin| ²é¿´: 876| ÆÀÂÛ: 0

ÕªÒª: Ĭɳ¶«ÐÂÐÍHIVÒ©ÎïDoravirineÔÚÃÀ½øÈëÕýʽÉó²é¡¡¡¡¡¾É½¶«Í¬Ö¾»áËù¡¿ÃÀ¹úÖÆÒ©¾ÞͷĬɳ¶«(Merck Co)½üÈÕÐû²¼£¬ÃÀ¹úʳƷºÍÒ©Îï¹ÜÀí¾Ö(FDA)ÒÑÊÜÀíÐÂÐÍHIVÒ©Îïdoravirine (MK-1439£¬DOR)µÄ2·ÝÐÂÒ©ÉêÇë(NDA)¡£DORÊÇÒ»ÖÖʵ ...

Ĭɳ¶«ÐÂÐÍHIVÒ©ÎïDoravirineÔÚÃÀ½øÈëÕýʽÉó²é



¡¡¡¡¡¾É½¶«Í¬Ö¾»áËù¡¿ÃÀ¹úÖÆÒ©¾ÞͷĬɳ¶«(Merck & Co)½üÈÕÐû²¼£¬ÃÀ¹úʳƷºÍÒ©Îï¹ÜÀí¾Ö(FDA)ÒÑÊÜÀíÐÂÐÍHIVÒ©Îïdoravirine (MK-1439£¬DOR)µÄ2·ÝÐÂÒ©ÉêÇë(NDA)¡£DORÊÇÒ»ÖÖʵÑéÐԷǺËÜÕÀàÄæ×ªÂ¼Ã¸ÒÖÖÆ¼Á(NNRTI)£¬Ä¿Ç°ÕýÔÚ¶à¸öÁÙ´²Ñо¿ÖнøÐпª·¢£¬ÓÃÓÚHIV-1³ÉÈ˸ÐȾÕßµÄÖÎÁÆ¡£Õâ2·ÝNDAÖУ¬ÆäÖÐÒ»·ÝÉêÇ뽫DOR×÷ΪһÖÖÿÈÕÒ»´ÎµÄµ¥Ò»Æ¬¼Á£¬ÁªºÏÆäËû¿¹Äæ×ªÂ¼²¡¶¾Ò©ÎΪ»¼ÕßÌṩһÖÖÁ¿Éí¶¨ÖÆµÄÍêÕûÖÎÁÆ·½°¸£»ÁíÒ»·ÝÉêÇ뽫DORÓëÀ­Ã×·ò¶¨(3TC)ºÍÌæÅµ¸£Î¤õ¥(TDF)×é³ÉµÄ¹Ì¶¨¼ÁÁ¿×éºÏµ¥Ò»Æ¬¼Á(DOR/3TC/TDF)£¬×÷ΪһÖÖÿÈÕÒ»´ÎµÄÍêÕûÖÎÁÆ·½°¸¡£FDAÒÑÖ¸¶¨Õâ2·ÝNDAµÄ´¦·½Ò©Óû§ÊÕ·Ñ·¨(PDUFA)Ä¿±êÈÕÆÚΪ2018Äê10ÔÂ23ÈÕ¡£

¡¡¡¡Ä¬É³¶«Ñо¿ÊµÑéÊÒÈ«ÇòÁÙ´²¿ª·¢¸±×ܲÃGeorge Hanna²©Ê¿±íʾ£¬×Ô´ÓHIVÁ÷ÐÐÒÔÀ´£¬Ä¬É³¶«Ò»Ö±ÖÂÁ¦ÓÚÑо¿ºÍÂú×ãHIVȺÌåµÄÐèÇó¡£DORÊǸù«Ë¾¿ª·¢³öµÄÒ»ÖÖеÄHIVÒ©Î½«Îª»¼ÕßÌṩһÖÖÓÐÒâÒåµÄÐÂÖÎÁÆÑ¡Ôñ£¬½â¾ö¸ÃÁìÓò´æÔÚµÄδÂú×ãÒ½ÁÆÐèÇó¡£

¡¡¡¡DORÁ½·ÝNDAµÄÌá½»£¬ÊÇ»ùÓÚ2ÏîÕýÔÚ¿ªÕ¹µÄIIIÆÚÁÙ´²Ñо¿(DRIVE-FORWARD£¬DRIVE-AHEAD)µÄÊý¾Ý¡£Õâ2¸öÑо¿·Ö±ðÆÀ¹ÀÁËDOR·Ö±ðÁªºÏ2ÖÖ±³¾°NRTI×éºÏµÄÍêÕûÖÎÁÆ·½°¸ÒÔ¼°DOR/3TC/TDF¹Ì¶¨¼ÁÁ¿×éºÏµ¥Ò»Æ¬¼ÁÍêÕûÖÎÁÆ·½°¸µÄÁÆÐ§ºÍ°²È«ÐÔ¡£³ýÁËÕâЩÑо¿Ö®Í⣬Ĭɳ¶«ÕýÔÚ¿ªÕ¹ÁíÒ»ÏîIIIÆÚÁÙ´²Ñо¿DRIVE-SHIFT£¬ÔÚ½ÓÊÜÆäËû¿¹Äæ×ªÂ¼²¡¶¾·½°¸ÊµÏÖ²¡¶¾Ñ§ÒÖÖÆµÄHIV-1³ÉÈ˸ÐȾÕßÖУ¬ÆÀ¹ÀתÏòDOR/3TC/TDF·½°¸µÄÁÆÐ§ºÍ°²È«ÐÔ¡£

¡¡¡¡DRIVE-FORWARD£ºDORµ¥Æ¬ÁªºÏ±³¾°NRTIÁÆÐ§Ç¿¾¢£¬ÑªÖ¬²ÎÊý¸üÓÅ

¡¡¡¡DRIVE-FORWARD(NCT02275780)ÊÇÒ»Ïî¶àÖÐÐÄ¡¢Ë«Ã¤¡¢Ëæ»ú¡¢·ÇÁÓЧÐÔÑо¿£¬ÔÚ769Àý¼ÈÍùδ½ÓÊÜ¿¹Äæ×ªÂ¼²¡¶¾Ò©ÎïÖÎÁÆ(³õÖÎ)HIV-1³ÉÈ˸ÐȾÕßÖпªÕ¹¡£Èë×é¸ÃÑо¿µÄ»¼ÕßÔÚÖÎÁÆÇ°µÄHIV-1 RNA¡Ý1000¿½±´/ºÁÉý£¬Ñо¿ÖУ¬ÕâЩ»¼ÕßÒÔ1£º1µÄ±ÈÀýËæ»ú½ÓÊÜDOR(100mg¼ÁÁ¿£¬Ã¿ÈÕÒ»´Î)£¬»òÀûÍÐÄÇΤ(ritonavir)ÔöЧµÄ´ï«ÄÇΤ(darunavir)(DRV+r£¬800mg+100mg£¬Ã¿ÈÕÒ»´Î)£¬¸÷×éͬʱ½ÓÊÜÑо¿ÕßËùÑ¡ÔñµÄ2ÖÖ³£ÓÃNRTI±³¾°·½°¸(TDF/FTC»òABC/3TC£¬Ã¿ÈÕÒ»´Î)£¬ÖÎÁÆÖ±ÖÁ96ÖÜ¡£¸ÃÑо¿µÄÖ÷ÒªÖÕµãÊÇÖÎÁƵÚ48ÖÜʱʵÏÖHIV RNA£¼50¿½±´/ºÁÉýµÄ»¼Õß±ÈÀý£¬Ô¤Ïȶ¨ÒåµÄ·ÇÁÓЧÐԱ߽çֵΪ10%¡£´ÎÒªÖÕµã°üÀ¨DORºÍDRV+r¶Ô¿Õ¸¹ÑªÖ¬µÄÓ°Ïì¡¢CD4+Tϸ°û¼ÆÊý´Ó»ùÏߵı仯£¬ÄÍÊÜÐÔ¡£

¡¡¡¡Ñо¿½á¹ûÏÔʾ£º(1)769ÀýÊÜÊÔÕßÖÐÓÐ766Àý½ÓÊÜÁËÑо¿Ò©Îï(ÿ¸öÖÎÁÆ×é383Àý)²¢ÄÉÈëÁËÁÆÐ§ºÍ°²È«ÐÔ·ÖÎö(ƽ¾ùÄêÁä35.2Ë꣬84%ÄÐÐÔ£¬73%°×ÈË£¬87%½ÓÊÜTDF/FTC)¡£ÔÚÖÎÁƵÚ48ÖÜ£¬DORÖÎÁÆ×éʵÏÖHIV-1 RNA£¼50¿½±´/ºÁÉýµÄ»¼Õß±ÈÀýΪ83.8%(n=321/383)£¬DRV+rÖÎÁÆ×éΪ79.9%(n=306/383£¬²îÒì=3.9%£¬95%CI[-1.6£¬9.4])£¬Êý¾Ý´ïµ½ÁË·ÇÁÓЧÐÔ±ê×¼¡£(2)ÔÚ»ùÏßHIV-1 RNA£¾100000¿½±´/ºÁÉýµÄÑÇ×éÖУ¬ÖÎÁƵÚ48ÖÜʱ£¬DORÖÎÁÆ×éºÍDRV+rÖÎÁÆ×éʵÏÖHIV-1 RNA£¼50¿½±´/ºÁÉýµÄ»¼Õß±ÈÀý·Ö±ðΪ81.0%(n=64/79)ºÍ76.4%(n=55/72)¡£(3)Ö÷Òª°²È«ÐÔÖÕµã·½Ãæ£¬²»Á¼Ê¼þ·¢ÉúÂÊ(×ÜÌå¡¢ÑÏÖØ¡¢Ò©ÎïÏà¹Ø¡¢ÖÎÁÆÍ£Ò©)ÔÚDORÖÎÁÆ×éºÍDRV+rÖÎÁÆ×éÏàËÆ£¬×î³£¼ûµÄÒ©ÎïÏà¹Ø²»Á¼Ê¼þ(£¾5%)Ϊ¸¹Ðº(5.5% vs 12.8%)¡¢¶ñÐÄ(6.5% vs 7.6%)ºÍÍ·Í´(6.0% vs 2.6%)¡£(4)´ÎÒªÖÕµã·½Ãæ£¬DORÖÎÁÆ×é¿Õ¸¹LDL-CºÍnon-HDL-CˮƽÏà¶Ô»ùÏß½µµÍ(·Ö±ðΪ£º-4.5mg/dLºÍ-5.3mg/dL)£¬DRV+rÖÎÁÆ×é¿Õ¸¹LDL-CºÍ·Ç-HDL-CˮƽÏà¶Ô»ùÏß¾ù±íÏÖÉý¸ß(·Ö±ðΪ£º+9.9mg/dL£¬+13.8mg/dL)£¬Êý¾Ý¾ßÓÐͳ¼ÆÑ§ÏÔÖø²îÒì(¿Õ¸¹LDL-C£º²îÒì=-14.6mg/dL£¬95%CI[-18.2£¬-11.1]£¬p£¼0.0001£»¿Õ¸¹non-HDL-C£º²îÒì=-19.3£¬95%CI[-23.3£¬-15.4]£¬p£¼0.0001)¡£

¡¡¡¡¸ÃÑо¿Ö¤Êµ£ºÔÚ³õÖÎHIV-1³ÉÈËȺÌåÖУ¬Óë2ÖÖ³£Óñ³¾°NRTI·½°¸ÁªºÏÓÃҩʱ£¬ÔÚÖÎÁƵÚ48ÖÜ£¬DOR±íÏÖ³öÁËÇ¿¾¢µÄÁÆÐ§£¬ÓëDRV+rÏà±È¾ßÓзÇÁÓЧÐÔ£¬²¢Óë»ùÏßHIV-1 RNAˮƽÎ޹ء£°²È«ÐÔ·½Ã棬DORµÄ°²È«ÐÔºÍÄÍÊÜÐÔÁ¼ºÃ£¬ÓëDRV+rÏà±È¾ßÓиüÓÅÔ½µÄѪ֬²ÎÊýÊôÐÔ¡£

¡¡¡¡DRIVE-AHEAD£ºDOR/3TC/TDF¸´·½µ¥Æ¬ÁÆÐ§Ç¿¾¢£¬Éñ¾­¾«Éñ°²È«ÐÔ¸üºÃ£¬ÑªÖ¬²ÎÊý¸üÓÅ

¡¡¡¡DRIVE-AHEAD(NCT02403674)ÊÇÒ»Ïî¶àÖÐÐÄ¡¢Ëæ»ú¡¢Ë«Ã¤¡¢·ÇÁÓЧÐÔÑо¿£¬ÔÚ734Àý¼ÈÍùδ½ÓÊÜ¿¹Äæ×ªÂ¼²¡¶¾Ò©ÎïÖÎÁÆ(³õÖÎ)HIV-1³ÉÈ˸ÐȾÕßÖпªÕ¹£¬ÆÀ¹ÀÁËÿÈÕÒ»´Î¹Ì¶¨¼ÁÁ¿×éºÏµ¥Ò»Æ¬¼ÁDOR/3TC/TDF(100mg/300mg/300mg)Ïà¶ÔÓÚÿÈÕÒ»´Î¹Ì¶¨¼ÁÁ¿×éºÏµ¥Ò»Æ¬¼ÁEFV/FTC/TDF(600mg/200mg/300mg)µÄÁÆÐ§ºÍ°²È«ÐÔ¡£Èë×é¸ÃÑо¿µÄ»¼ÕßÔÚÖÎÁÆÇ°µÄHIV-1 RNA¡Ý1000¿½±´/ºÁÉý£¬Ñо¿ÖУ¬ÕâЩ»¼ÕßÒÔ1£º1µÄ±ÈÀýËæ»ú½ÓÊÜDOR/3TC/TDF»òEFV/FTC/TDFÖÎÁÆÖ±ÖÁ96ÖÜ£¬Ëæ»ú»¯·Ö×éͨ¹ýHIV-1 RNAˮƽ(¡Ü/£¾100000¿½±´/ºÁÉý)ºÍÒÒ¸Î/±û¸Î¹²¸ÐȾ(ÊÇ/·ñ)½øÐзּ¶¡£Ñо¿µÄÖ÷ÒªÁÆÐ§ÖÕµãÊÇÖÎÁƵÚ48ÖÜʱHIV RNA£¼50¿½±´/ºÁÉýµÄ»¼Õß±ÈÀý£¬Ô¤Ïȶ¨ÒåµÄ·ÇÁÓЧÐԱ߽çֵΪ10%¡£Ö÷Òª°²È«ÖÕµãÊÇÖÎÁÆ48ÖÜÆÚ¼ä·¢ÉúÏÂÊöÉñ¾­¾«Éñ²»Á¼Ê¼þµÄ»¼Õß±ÈÀý£ºÍ·ÔΡ¢Ë¯ÃßÕϰ­ºÍÎÉÂÒ¡¢¸Ð¾õ¸Ä±ä¡£´ÎÒªÖÕµã°üÀ¨£ºDOR/3TC/TDFºÍEFV/FTC/TDF¶Ô¿Õ¸¹ÑªÖ¬µÄÓ°Ïì¡¢CD4+Tϸ°û¼ÆÊý´Ó»ùÏߵı仯£¬ÄÍÊÜÐÔ¡£

¡¡¡¡Ñо¿½á¹ûÈçÏÂËùʾ£º(1)734ÀýÊÜÊÔÕßÖÐÓÐ728Àý½ÓÊÜÁËÑо¿Ò©Îï(ÿ¸öÖÎÁÆ×é364Àý)²¢ÄÉÈëÁË·ÖÎö(ƽ¾ùÄêÁä33Ë꣬85%ÄÐÐÔ£¬48%°×ÈË)¡£ÔÚÖÎÁƵÚ48ÖÜ£¬DOR/3TC/TDFÖÎÁÆ×éʵÏÖHIV-1 RNA£¼50¿½±´/ºÁÉýµÄ»¼Õß±ÈÀýΪ84.3%£¬FEV/FTC/TDFÖÎÁÆ×éΪ80.8%(²îÒì=3.5%£¬95%CI[-2.0£¬9.0])¡£(2)Ö÷Òª°²È«ÐÔÖÕµã·½Ãæ£¬DOR/3TC/TDFÖÎÁÆ×éÍ·ÔΡ¢Ë¯ÃßÕϰ­ºÍÎÉÂÒ¡¢¸Ð¾õ¸Ä±ä·¢ÉúÂʱÈEFV/FTC/TDFÖÎÁÆ×éµÍ(·Ö±ðΪ£º8.8% vs 37.1%[p£¼0.001]£¬12.1% vs 25.5%[p£¼0.001]£¬4.4% vs 8.2%[p=0.033])¡£(3)´ÎÒªÖÕµã·½Ãæ£¬DOR/3TC/TDFÖÎÁÆ×é¿Õ¸¹LDL-CºÍnon-HDL-CˮƽÏà¶Ô»ùÏß½µµÍ(·Ö±ðΪ£º-1.6mg/dLºÍ-3.0mg/dL)£¬EFV/FTC/TDFÖÎÁÆ×é¿Õ¸¹LDL-CºÍ·Ç-HDL-CˮƽÏà¶Ô»ùÏß¾ù±íÏÖÉý¸ß(·Ö±ðΪ£º+0.7mg/dL£¬+13.3mg/dL)£¬Êý¾Ý¾ßÓÐͳ¼ÆÑ§ÏÔÖø²îÒì(¿Õ¸¹LDL-C£º²îÒì=-10.0mg/dL£¬95%CI[-13.5£¬-6.5]£¬p£¼0.0001£»¿Õ¸¹non-HDL-C£º²îÒì=-17.0£¬95%CI[-20.9£¬-13.2]£¬p£¼0.0001)¡£

¡¡¡¡¸ÃÑо¿Ö¤Êµ£ºÔÚ³õÖÎHIV-1³ÉÈËȺÌåÖУ¬ÔÚÖÎÁƵÚ48ÖÜ£¬DOR/3TC/TDFµ¥Ò»Æ¬¼Á·½°¸ÓëEFV/FTC/TDFµ¥Ò»Æ¬¼Á·½°¸ÔÚÁÆÐ§·½Ãæ¾ßÓзÇÁÓЧÐÔºÍÏàËÆÐÔ£¬²¢Óë»ùÏßHIV-1 RNAˮƽÎ޹ء£DOR/3TC/TDF·½°¸µÄ°²È«ÐÔºÍÄÍÊÜÐÔÁ¼ºÃ£¬Éñ¾­¾«ÉñʼþÃ÷ÏÔÉÙÓÚEFV/FTC/TDF·½°¸£¬Í¬Ê±¾ßÓиüºÃµÄѪ֬²ÎÊý¡£(ÐÂÀËÒ½Ò©±àÒë/newborn)

¡¡¡¡ÎÄÕ²ο¼À´Ô´£ºFDA Accepts New Drug Applications for Merck¡¯s Doravirine, the Company¡¯s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection

¡¡¡¡(À´Ô´£ºÐÂÀËÒ½Ò©ÐÂÎÅ)


ÏÊ»¨

ÎÕÊÖ

À×ÈË

·¹ý

¼¦µ°

Archiver|ÊÖ»ú°æ|СºÚÎÝ|ÉϺ£Í¬Ö¾ - ÉϺ£Í¬Ö¾ÁÄÌìÊÒ - ÉϺ£Í¬Ö¾½»ÓÑ  

GMT+8, 2023-2-5 18:47 , Processed in 0.082005 second(s), 18 queries .

Powered by ͬ־´óȫվ¶ÔÓÚÈκΰüº¬ÓÚ¡¢¾­ÓÉ¡¢Á´½Ó¡¢ÏÂÔØ»ò´ÓÈκÎÓë±¾ÍøÕ¾ÓйطþÎñ£¨ÒÔϼò³Æ[·þÎñ]£©Ëù»ñµÃ µÄÐÅÏ¢¡¢ÄÚÈÝ»ò¹ã¸æ£¨ÒÔϼò³Æ[×ÊÁÏ]£©£¬²»ÉùÃ÷»ò±£Ö¤ÆäÕýÈ·ÐÔ»ò¿É¿¿ÐÔ¡£ÄúÓڴ˽ÓÊܲ¢³ÐÈÏÐÅÀµÈκΠ[×ÊÁÏ]Ëù·¢ÉúµÄ·çÏÕ¶¼Ó¦×ÔÐге£¡£¶ÔÓÚÒò[·þÎñ]¡¢[×ÊÁÏ]ËùÉúµÄÈκÎÖ±½Ó¡¢¼ä½Ó¡¢¸½´øµÄ»òÒò´Ë¶øµ¼Ö µÄÑÜÉúÐÔËðʧ¸Å²»¸ºÔð¡£ °²»ÕÍ¬Ö¾ÍøÕ¾ÎªÃâ·ÑÍøÖ·Õ¾£¬ËùÓÐÁ¬½Ó¾ùÀ´×ÔÍøÉÏ£¬ÆäÏà¹ØÄÚÈÝÒ»¸ÅÓë±¾Õ¾Î޹أ¬±¾Õ¾²»¶ÔÏà¹ØÍøÕ¾ÄÚÈÝ ¸ºÔð£¡ÈçÄú·¢ÏÖ±¾Õ¾ÓÐÈκηǷ¨²»Á¼Á¬½Ó,ÇëÁ¢¼´¸æÖ®ÎÒÃÇ,ÎÒÃǽ«ÔÚµÚһʱ¼äÄÚɾ³ý.ÎÒÃǼá¾öÖ§³ÖºÍÅä ºÏרÏîÐж¯ X3.2

© 2001-2013 Comsenz Inc.

·µ»Ø¶¥²¿